{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:53:15Z","timestamp":1779101595056,"version":"3.51.4"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.cct.2017.07.021","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T20:23:19Z","timestamp":1500754999000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Differing antidepressant maintenance methodologies"],"prefix":"10.1016","volume":"61","author":[{"given":"Daniel J.","family":"Safer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2017.07.021_bb0005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0140-6736(03)12599-8","article-title":"Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review","volume":"361","author":"Geddes","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.13r08722","article-title":"Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration","volume":"75","author":"Borges","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/15622975.2014.1001786","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2. Maintenance treatment of major depressive disorder-update 2015","volume":"16","author":"Bauer","year":"2015","journal-title":"World J. Biol. Psychiatry"},{"issue":"S15","key":"10.1016\/j.cct.2017.07.021_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1017\/S1092852900015212","article-title":"Preventing relapse and recurrence of depression: a brief review of therapeutic options","volume":"11","author":"Thase","year":"2006","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.cct.2017.07.021_bb0025","author":"Prozac"},{"key":"10.1016\/j.cct.2017.07.021_bb0030","author":"Lexapro"},{"key":"10.1016\/j.cct.2017.07.021_bb0035","author":"Cymbalta"},{"key":"10.1016\/j.cct.2017.07.021_bb0040","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4088\/JCP.v69n0910","article-title":"Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials","volume":"69","author":"Kaymaz","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.cct.2017.07.021_bb0045","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11920-005-0061-0","article-title":"Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders","volume":"7","author":"Kessing","year":"2005","journal-title":"Curr. Psychiatry Rep."},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1176\/appi.ajp.157.2.229","article-title":"Multiple recurrences of major depressive disorder","volume":"157","author":"Solomon","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jad.2003.11.008","article-title":"Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up?","volume":"82","author":"Pintor","year":"2004","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.31887\/DCNS.2008.10.4\/espaykel","article-title":"Partial remission, residual symptoms, and relapse in depression","volume":"20","author":"Paykel","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.cct.2017.07.021_bb0065","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2017.07.021_bb0070","first-page":"250","article-title":"Psychosocial and clinical predictors of response to pharmacotherapy for depression","volume":"27","author":"Bagby","year":"2002","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.cct.2017.07.021_bb0075","series-title":"Handbook of Depression","first-page":"31","year":"2009"},{"issue":"8","key":"10.1016\/j.cct.2017.07.021_bb0080","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4088\/JCP.v69n0807","article-title":"Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report","volume":"69","author":"Gilmer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/da.22045","article-title":"Predictive socioeconomic and clinical profiles of antidepressant response and remission","volume":"30","author":"Jain","year":"2013","journal-title":"Depress. Anxiety"},{"issue":"7","key":"10.1016\/j.cct.2017.07.021_bb0090","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4088\/JCP.13m08727","article-title":"Prognostic subgroups for citalopram response in the STAR*D trial","volume":"75","author":"Jakubovski","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.cct.2017.07.021_bb0095","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1176\/ajp.2006.163.9.1542","article-title":"Predictors of relapse in a prospective study of fluoxetine treatment of major depression","volume":"163","author":"McGraph","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jad.2014.08.003","article-title":"Treatment and outcomes for patients with depression who are partial responders to SSRI treatment: post-hoc analysis findings from the FINDER European observation study","volume":"109","author":"Lenox-Smith","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/JCP.0000000000000263","article-title":"Duration of initial antidepressant treatment and subsequent relapse of major depression","volume":"35","author":"Baldessarini","year":"2015","journal-title":"J. Clin. Psychpharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0110","first-page":"1","article-title":"Deterioration\/relapse of depression during pregnancy in Japanese women associated with interruption of antidepressant mediations","volume":"22","author":"Suzuki","year":"2016","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"10.1016\/j.cct.2017.07.021_bb0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000371865","article-title":"New classification of selective serotonin reuptake inhibitor withdrawal","volume":"84","author":"Chouinard","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.cct.2017.07.021_bb0120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1600-0447.1991.tb03197.x","article-title":"Relationship of dose to antidepressant prophylactic efficacy","volume":"84","author":"Peselow","year":"1991","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.cct.2017.07.021_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4088\/JCP.v59n0504","article-title":"Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study","volume":"59","author":"Franchini","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000104702","article-title":"Antidepressant dose reduction and the risk of relapse in major depressive disorder","volume":"76","author":"Papakostas","year":"2007","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.cct.2017.07.021_bb0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0165-0327(93)90001-Z","article-title":"Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression","volume":"27","author":"Frank","year":"1993","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.cct.2017.07.021_bb0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/appi.ajp.2016.15111444","article-title":"Outcomes of citalopram dosage risk mitigation in a veteran population","volume":"173","author":"Rector","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0145","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.bp.115.168971","article-title":"Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression; randomized controlled non-inferiority trial","author":"Huijbers","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0150","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jad.2012.12.009","article-title":"Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5)","volume":"148","author":"Licht","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.cct.2017.07.021_bb0155","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/JCP.0b013e31803308e1","article-title":"Impact of study design on the results of continuation studies of antidepressants","volume":"27","author":"Zimmerman","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0165","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jpsychires.2007.10.004","article-title":"The persistence of the placebo response in antidepressant trials","volume":"42","author":"Khan","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.cct.2017.07.021_bb0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cpr.2011.09.003","article-title":"Relapse and recurrence prevention in depression; current research and future prospects","volume":"31","author":"Beshai","year":"2011","journal-title":"Clin. Psychol. Rev."},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0175","first-page":"1","article-title":"Blue again: pertubational effects of antidepressants suggest monoaminergic homeostasis in major depression","volume":"159","author":"Andrews","year":"2011","journal-title":"Front. Psychol."},{"issue":"10","key":"10.1016\/j.cct.2017.07.021_bb0180","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1176\/ps.2008.59.10.1121","article-title":"Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants","volume":"59","author":"Hansen","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.cct.2017.07.021_bb0185","first-page":"1","article-title":"Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analysis of controlled trials","author":"Sim","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hup.1033","article-title":"Relapse rates in long-term antidepressant drug therapy","volume":"24","author":"Williams","year":"2009","journal-title":"Human Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1176\/ajp.156.2.202","article-title":"Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy","volume":"156","author":"Reynolds","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004850-199803000-00002","article-title":"Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study","volume":"13","author":"Montgomery","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004850-199300830-00008","article-title":"A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression","volume":"8","author":"Montgomery","year":"1993","journal-title":"Intern. Clin. Psychophamacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eurpsy.2006.03.004","article-title":"Duloxetine in the treatment of major depressive disorder: a placebo-and paroxetine-controlled trial","volume":"21","author":"Perahia","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0215","first-page":"137","article-title":"Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates","volume":"11","author":"Entsuah","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0032-1306348","article-title":"St John's Wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT","volume":"45","author":"Sarris","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0225","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","article-title":"Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"14","author":"Detke","year":"2004","journal-title":"Eur. Neuropsychopharmaocol."},{"issue":"Suppl. 2","key":"10.1016\/j.cct.2017.07.021_bb0230","first-page":"23S","article-title":"A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression","volume":"13","author":"Claghorn","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00004714-199404000-00003","article-title":"A comparison of venlafaxine, trazodone, and placebo in major depression","volume":"14","author":"Cunningham","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0240","first-page":"165","article-title":"Long-term treatment of depression with nefazadone","volume":"30","author":"Anton","year":"1994","journal-title":"Psychopharmacol. Bull."},{"issue":"6","key":"10.1016\/j.cct.2017.07.021_bb0245","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00004714-200012000-00010","article-title":"Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy","volume":"20","author":"Aberg-Wistedt","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0250","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/hup.470100505","article-title":"A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression","volume":"10","author":"Van Moffaert","year":"1995","journal-title":"Human Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0255","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/da.20894","article-title":"Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination","volume":"28","author":"Rucci","year":"2011","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.cct.2017.07.021_bb0260","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.biopsych.2007.04.040","article-title":"The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the acute and continuation phases","volume":"62","author":"Keller","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0265","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.pnpbp.2005.11.020","article-title":"Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychological and genetic variables","volume":"30","author":"Dotoli","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0270","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00004714-200210000-00006","article-title":"Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder","volume":"22","author":"Perlis","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0275","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1176\/appi.psy.45.5.419","article-title":"Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment","volume":"45","author":"Iosifescu","year":"2004","journal-title":"Psychosomatics"},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1520-6394(2001)13:1<38::AID-DA6>3.0.CO;2-7","article-title":"Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly","volume":"13","author":"Bump","year":"2001","journal-title":"Depress Anxiety"},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0285","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v58n0303","article-title":"A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression","volume":"58","author":"Franchini","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0290","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0165-0327(97)00153-5","article-title":"Long-term treatment of geropsychiatric depressed patients with venlafaxine","volume":"46","author":"Amore","year":"1997","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0295","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1192\/bjp.170.3.268","article-title":"The effect of treatment on the two-year course of late-life depression","volume":"170","author":"Flint","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.22177","article-title":"Acute and chronic stress exposure predicts 1-yeare recurrence in adult outpatients with residual depression symptoms following response to treatment","volume":"31","author":"Harkness","year":"2014","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.cct.2017.07.021_bb0305","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/gps.2076","article-title":"A pilot randomized controlled trial of a brief cognitive behavioural group intervention to reduce recurrence rates in late life depression","volume":"24","author":"Wilkinson","year":"2009","journal-title":"Intern. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2017.07.021_bb0310","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1192\/bjp.171.4.328","article-title":"Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression","volume":"171","author":"Blackburn","year":"1997","journal-title":"Brit. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0315","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1037\/a0013786","article-title":"Mindfulness-based cognitive therapy to prevent relapse in recurrent depression","volume":"76","author":"Kuyken","year":"2008","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2017.07.021_bb0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jad.2015.08.023","article-title":"Adding mindfulness-based cognitive therapy to maintenance antidepressant medication for prevention of relapse\/recurrence in major depressive disorder: randomized controlled trial","volume":"187","author":"Huijbers","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0325","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-0327(86)90050-9","article-title":"A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both","volume":"10","author":"Blackburn","year":"1986","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0330","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archpsyc.56.9.829","article-title":"Prevention of relapse in residual depression by cognitive therapy: a controlled trial","volume":"56","author":"Paykel","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0335","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(14)62222-4","article-title":"Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomized controlled trial","volume":"386","author":"Kuyken","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2017.07.021_bb0340","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1176\/ajp.151.9.1295","article-title":"Cognitive behavioral treatment of residual symptoms in primary major depressive disorder","volume":"151","author":"Fava","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.281.1.39","article-title":"Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression","volume":"281","author":"Reynolds","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2017.07.021_bb0350","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJMoa052619","article-title":"Maintenance treatment of major depression in old age","volume":"354","author":"Reynolds","year":"2006","journal-title":"New Eng. J. Med."},{"issue":"12","key":"10.1016\/j.cct.2017.07.021_bb0355","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archpsyc.1990.01810240013002","article-title":"Three-year outcomes of maintenance therapies in recurrent depression","volume":"47","author":"Frank","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.cct.2017.07.021_bb0360","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamapsychiatry.2014.1054","article-title":"Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial","volume":"71","author":"Hollon","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1037\/a0035036","article-title":"Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: a randomized dismantling trial","volume":"82","author":"Williams","year":"2014","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2017.07.021_bb0370","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jad.2008.08.002","article-title":"Eighteen months of drug treatment for depression: predicting relapse and recovery","volume":"114","author":"Mulder","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0375","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.brat.2010.04.006","article-title":"The effects of mindfulness-based cognitive therapy on recurrence of depressive epidodes, mental health and quality or life: a randomized controlled study","volume":"48","author":"Godfrin","year":"2010","journal-title":"Behav. Res. Therap."},{"issue":"4","key":"10.1016\/j.cct.2017.07.021_bb0380","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1037\/0022-006X.68.4.615","article-title":"Prevention of relapse\/recurrence in major depression by mindfulness-based cognitive therapy","volume":"68","author":"Teasdale","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1037\/0022-006X.72.1.31","article-title":"Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects","volume":"72","author":"Ma","year":"2004","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2017.07.021_bb0390","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jad.2009.07.007","article-title":"Depression relapse prophylaxis with mindfulness-based cognitive therapy: replication and extension in the Swiss health care system","volume":"122","author":"Bondolfi","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000110056","article-title":"Continuation and maintenance use of antidepressants in recurrent depression","volume":"77","author":"Blocking","year":"2008","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.cct.2017.07.021_bb0400","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.yic.0000199452.16682.b8","article-title":"Response, remission and relapse in relation to adherence in primary care treatment of depression; a 2-year outcome study","volume":"21","author":"Akerblad","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0405","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/S0140-6736(03)13710-5","article-title":"Relapse prevention and antidepressants","volume":"361","author":"Geddes","year":"2003","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.cct.2017.07.021_bb0410","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1520-6394(1998)8:1+<43::AID-DA7>3.0.CO;2-C","article-title":"Extended antidepressant maintenance and discontinuation syndromes","volume":"8","author":"Maixner","year":"1998","journal-title":"Depress. Anxiety"},{"issue":"6","key":"10.1016\/j.cct.2017.07.021_bb0415","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10673229809003578","article-title":"Discontinuing antidepressant treatment in major depression","volume":"5","author":"Viguera","year":"1998","journal-title":"Harv. Rev. Psychiat."},{"issue":"5","key":"10.1016\/j.cct.2017.07.021_bb0420","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/JCP.0000000000000372","article-title":"Medication nonadherence, professional subjects, and apparent placebo responders","volume":"35","author":"McCann","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0425","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archpsyc.1992.01820100046009","article-title":"Differential relapse following cognitive therapy and pharmaocotherapy for depression","volume":"49","author":"Evans","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.cct.2017.07.021_bb0430","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1176\/ajp.155.9.1247","article-title":"Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment","volume":"155","author":"Reimherr","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0435","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/ajp.143.1.18","article-title":"Continuation drug therapy for major depressive episodes: how long should it be maintained?","volume":"143","author":"Prien","year":"1986","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.cct.2017.07.021_bb0440","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.4088\/JCP.v67n1115","article-title":"Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial","volume":"67","author":"Kornstein","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0445","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.59.8.723","article-title":"Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo","volume":"59","author":"Kocsis","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.cct.2017.07.021_bb0450","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004850-199503001-00006","article-title":"Citalpram in doses of 20\u201360mg is effective in depression relapse prevention: a placebo-controlled 6 month study","volume":"10","author":"Robert","year":"1995","journal-title":"Intern. Clin. Psychopharm."},{"issue":"5","key":"10.1016\/j.cct.2017.07.021_bb0455","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.295.5.499","article-title":"Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment","volume":"295","author":"Cohen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2017.07.021_bb0460","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/YIC.0b013e32832fbb5a","article-title":"Discontinuation symptoms and taper\/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0465","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpsychires.2003.10.004","article-title":"Extended release venlafaxine in relapse prevention for patients with major depressive disorder","volume":"38","author":"Simon","year":"2004","journal-title":"J. Psychiatr. Res."},{"issue":"9","key":"10.1016\/j.cct.2017.07.021_bb0470","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1176\/ajp.2006.163.9.1542","article-title":"Predictors of relapse in a prospective study of fluoxetine treatment of major depression","volume":"163","author":"McGrath","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0475","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1176\/ajp.137.3.370","article-title":"Maintenance therapy with amitriptyline: a controlled trial","volume":"137","author":"Stein","year":"1980","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0480","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1991.01810280029004","article-title":"Methodologic issues in maintenance therapy clinical trials","volume":"48","author":"Greenhouse Greenhouse","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0485","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation syndrome: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother. Psychosom."},{"issue":"6","key":"10.1016\/j.cct.2017.07.021_bb0490","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1017\/S1461145706007462","article-title":"Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia","volume":"10","author":"Fava","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0495","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00228-005-0921-x","article-title":"Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation","volume":"61","author":"Van Geffen","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"Suppl. 7","key":"10.1016\/j.cct.2017.07.021_bb0500","first-page":"11","article-title":"Antidepressant discontinuation: a review of the literature","volume":"58","author":"Lejoyeux","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0505","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/WNF.0000000000000139","article-title":"Characteristics of escitalopram discontinuation syndrome: a preliminary study","volume":"39","author":"Yasui-Furukori","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0510","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4088\/JCP.v66n1015","article-title":"Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms","volume":"66","author":"Sir","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0515","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jad.2005.09.003","article-title":"Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder","volume":"89","author":"Perahia","year":"2005","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 7","key":"10.1016\/j.cct.2017.07.021_bb0520","first-page":"37","article-title":"Clinical management of antidepressant discontinuation","volume":"58","author":"Rosenbaum","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0525","first-page":"4","article-title":"Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling","volume":"26","author":"Einarson","year":"2001","journal-title":"J. Psychiatry Neurosci."},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2017.07.021_bb0535","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0540","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00004850-200209000-00002","article-title":"Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine","volume":"17","author":"Judge","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0545","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S1461145705006358","article-title":"Discontinuation symptoms in depression and anxiety disorders","volume":"10","author":"Baldwin","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/11599450-000000000-00000","article-title":"Studies of long-term use of antidepressants","volume":"26","author":"El-Mallakh","year":"2012","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.cct.2017.07.021_bb0555","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1176\/ajp.156.6.943","article-title":"Recurrence of first-spisode geriatric depression after discontinuation of maintenance antidepressants","volume":"156","author":"Flint","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2017.07.021_bb0560","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004714-200108000-00009","article-title":"Fluoxetine in the prevention of depressive recurrences: a double-blind study","volume":"21","author":"Gilaberte","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0565","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3109\/00048671003705441","article-title":"Meta-analysis of relapse prevention antidepressant trials in depressive disorders","volume":"44","author":"Glue","year":"2010","journal-title":"Aust. NZ J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0327(84)90002-8","article-title":"Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment","volume":"6","author":"Tyrer","year":"1984","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0575","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00406-009-0031-3","article-title":"Type of residual symptom and risk of relapse during the continuation\/maintenance phase of treatment of major depressive disorder with selective serotonin reuptake inhibitor fluoxetine","volume":"260","author":"Yang","year":"2010","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.cct.2017.07.021_bb0580","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.psychres.2014.11.022","article-title":"Prophlactic efficacy of fluoxetine, escitalpram, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up","volume":"225","author":"Peselow","year":"2015","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.cct.2017.07.021_bb0585","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/JCP.0000000000000564","article-title":"Raising the minimum effective dose of serotonin reuptake inhibitor antidepressants: adverse drug effects","volume":"36","author":"Safer","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.cct.2017.07.021_bb0590","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4088\/JCP.v60n1210","article-title":"Two year maintenance treatment with citalopram, 20mg, in unipolar subjects with high recurrence rate","volume":"60","author":"Franchini","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0595","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1034\/j.1399-5618.1999.10106.x","article-title":"Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications","volume":"1","author":"Baldessarini","year":"1999","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0600","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","article-title":"Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar1 disorder responding to acute treatment with olanzapine","volume":"163","author":"Tohen","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2017.07.021_bb0605","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/0269881107085238","article-title":"Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study","volume":"22","author":"Franks","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.cct.2017.07.021_bb0610","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1176\/appi.ajp.2010.09060880","article-title":"Illness risk following rapid versus gradual discontinuation of antidepressants","volume":"167","author":"Baldessarini","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0615","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.mehy.2012.05.029","article-title":"Treating anxiety by discontinuing antidepressants: a case series","volume":"79","author":"Phelps","year":"2012","journal-title":"Med. Hypotheses"},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0620","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/070674370304800217","article-title":"New dosage-reduction regime to avoid paroxetine discontinuation","volume":"48","author":"Yanez","year":"2003","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.cct.2017.07.021_bb0625","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/bmb\/57.1.145","article-title":"Continuation and maintenance therapy in depression","volume":"57","author":"Pakel","year":"2001","journal-title":"Br. Med. Bull."},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0630","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1176\/appi.ajp.159.3.469","article-title":"Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?","volume":"159","author":"Zimmerman","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0635","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/JCP.0b013e318058263f","article-title":"Relevance of exclusion criteria in antidepressant clinical trials: a replication study","volume":"27","author":"Zetin","year":"2007","journal-title":"J. Clin. Psychophamacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0640","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/gps.2211","article-title":"Design characteristics that influence attrition in geriatric antidepressant tirals: meta-analysis","volume":"24","author":"Heo","year":"2009","journal-title":"Intern. J. Geriat. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0645","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/sj.npp.1301361","article-title":"Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports","volume":"32","author":"Khan","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cct.2017.07.021_bb0650","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/YIC.0b013e328330adb2","article-title":"Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute treatment of major depression","volume":"25","author":"Thase","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.cct.2017.07.021_bb0655","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"74","author":"Khin","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0660","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1192\/bjp.160.2.217","article-title":"Sertraline in the prevention of depression","volume":"160","author":"Doogan","year":"1992","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2017.07.021_bb0665","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1176\/appi.ajp.161.5.836","article-title":"A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder","volume":"161","author":"Lepine","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0670","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000318293","article-title":"Efficacy and effectiveness of antidepressants: current status of research","volume":"79","author":"Pigott","year":"2010","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.cct.2017.07.021_bb0675","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jad.2010.04.011","article-title":"Psychosocial outcomes in patient with recurrent major depressive disorder during two years of maintenance treatment with venalafaxine extended release","volume":"126","author":"Trivedi","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0680","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jama.282.4.323","article-title":"Relapse of depressive symptoms after discontinuing sertraline","volume":"282","author":"Keller","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.cct.2017.07.021_bb0685","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.13m08797","article-title":"The role of expectancy in placebo and nocebo effects in antidepressant trials","volume":"75","author":"Ruherford","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0690","first-page":"133","article-title":"Better safe than sorry\u2014why patients prefer to stop using selective serotonin reuptake inhibitor (SSRI) antidepressants but are afraid to do so: results of a qualitative study","volume":"2","author":"Verbeek-Heida","year":"2006","journal-title":"Chronic Illn."},{"key":"10.1016\/j.cct.2017.07.021_bb0695","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0895-4356(93)90163-U","article-title":"Randomized discontinuation trials: utility and efficiency","volume":"9","author":"Kopec","year":"1993","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0700","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/JGP.0b013e3181256b1d","article-title":"Makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression","volume":"16","author":"Sneed","year":"2008","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0705","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/mpr.1391","article-title":"Improving study design for antidepressant effectiveness assessment","volume":"22","author":"Naudet","year":"2013","journal-title":"Int. J. Methods Psychiatr. Res."},{"issue":"8","key":"10.1016\/j.cct.2017.07.021_bb0710","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1742-1241.2008.01808.x","article-title":"The impact of analytic method on interpretation of outcomes in longitudinal clinical trials","volume":"62","author":"Prakash","year":"2008","journal-title":"Int. J. Clin. Pract."},{"issue":"12","key":"10.1016\/j.cct.2017.07.021_bb0715","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1592\/phco.29.12.1408","article-title":"Last-observation-carried forward imputation method in clinical efficacy trials; review of 352 antidepressant studies","volume":"29","author":"Woolley","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.cct.2017.07.021_bb0720","article-title":"Pretreatment attrition and formal withdrawal during treatment and their predictors","volume":"16","author":"AM","year":"2014","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.cct.2017.07.021_bb0725","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bjp.174.4.297","article-title":"Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomized clinical trials","volume":"174","author":"Bollini","year":"1999","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2017.07.021_bb0730","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/wps.20241","article-title":"Antidepressants versus placebo in major depression: an overview","volume":"14","author":"Khan","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0735","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199901000-00002","article-title":"Double-blind, placebo-substitution study nafazodone in the prevention of relapse during continuation treatment of outpatients with major depression","volume":"14","author":"Feiger","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0740","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0165-0327(84)90023-5","article-title":"Attrition in maintenance therapy for recurrent depression: a preliminary report","volume":"6","author":"Jacob","year":"1984","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0745","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.euroneuro.2008.06.006","article-title":"Continuation and long term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression\u2014a double-blind, randomized, placebo controlled long-term trial","volume":"18","author":"Kasper","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.cct.2017.07.021_bb0750","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/da.20541","article-title":"Income and attrition in the treatment of depression: a STAR*D report","volume":"26","author":"Warden","year":"2009","journal-title":"Depress. Anxiety"},{"issue":"5","key":"10.1016\/j.cct.2017.07.021_bb0755","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1017\/S003329170300744X","article-title":"Remission and recurrence of depression in the maintenance era: long term outcome in a Cambridge cohort","volume":"33","author":"Kennedy","year":"2003","journal-title":"Psychol. Med."},{"key":"10.1016\/j.cct.2017.07.021_bb0760","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-0327(97)00199-7","article-title":"A meta-analysis of the effects of cognitive therapy in depressed patients","volume":"49","author":"Gloaguen","year":"1998","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2017.07.021_bb0765","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0165-1781(01)00336-5","article-title":"Long-term treatment with citalopram in patients with highly recurrent forms of unipolar depression","volume":"105","author":"Franchini","year":"2001","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0770","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1037\/0022-006X.73.1.78","article-title":"Two-year prospective naturalistic study of remission from major depressive disorder as a function of personality disorder comorbidity","volume":"73","author":"Grilo","year":"2005","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0775","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1520-6394(1998)7:1<32::AID-DA4>3.0.CO;2-7","article-title":"Fluoxetine in child and adolescent depression: acute and maintenance treatment","volume":"7","author":"Emslie","year":"1998","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.cct.2017.07.021_bb0780","first-page":"E1","article-title":"Treatment of adult depression in the United States","author":"Olfson","year":"2016","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0785","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamainternmed.2016.7507","article-title":"Adult utilization of psychiatric drugs and differences by sex, age, and race","volume":"177","author":"Moore","year":"2017","journal-title":"JAMA Int. Med."},{"issue":"8","key":"10.1016\/j.cct.2017.07.021_bb0790","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/archgenpsychiatry.2009.81","article-title":"National patterns in antidepressant medication treatment","volume":"66","author":"Olfson","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0795","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.bp.109.076448","article-title":"Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis","volume":"198","author":"Barbui","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0800","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-244X-9-38","article-title":"Persistence and compliance to antidepressant treatment in patients with depression: a chart review","volume":"16","author":"Sawada","year":"2009","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2017.07.021_bb0805","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1176\/appi.ajp.163.1.101","article-title":"Continuity of antidepressant treatment for adults with depression in the United States","volume":"163","author":"Olfson","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0810","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2008.07.011","article-title":"Adherence to continuation and maintenance antidepressant use in recurrent depression","volume":"115","author":"ten Doesschate","year":"2009","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.cct.2017.07.021_bb0815","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4088\/JCP.13m08443","article-title":"National trends in long-term use of antidepressant medications: results from the US National Health and Nutrition Examination Survey","volume":"72","author":"Mojtabai","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.07.021_bb0820","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00127-010-0317-9","article-title":"The natural course and outcome of major depressive disorder in primary care: the PERDICT-NL study","volume":"47","author":"Stegenga","year":"2012","journal-title":"Soc. Psychiatry Epidemiol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714417301210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714417301210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:25:03Z","timestamp":1750785903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714417301210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":164,"alternative-id":["S1551714417301210"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2017.07.021","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differing antidepressant maintenance methodologies","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2017.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}